These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 34035409)

  • 1. Base-edited CAR T cells for combinational therapy against T cell malignancies.
    Georgiadis C; Rasaiyaah J; Gkazi SA; Preece R; Etuk A; Christi A; Qasim W
    Leukemia; 2021 Dec; 35(12):3466-3481. PubMed ID: 34035409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.
    Cooper ML; Choi J; Staser K; Ritchey JK; Devenport JM; Eckardt K; Rettig MP; Wang B; Eissenberg LG; Ghobadi A; Gehrs LN; Prior JL; Achilefu S; Miller CA; Fronick CC; O'Neal J; Gao F; Weinstock DM; Gutierrez A; Fulton RS; DiPersio JF
    Leukemia; 2018 Sep; 32(9):1970-1983. PubMed ID: 29483708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.
    Gomes-Silva D; Srinivasan M; Sharma S; Lee CM; Wagner DL; Davis TH; Rouce RH; Bao G; Brenner MK; Mamonkin M
    Blood; 2017 Jul; 130(3):285-296. PubMed ID: 28539325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TCRαβ/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy.
    Rasaiyaah J; Georgiadis C; Preece R; Mock U; Qasim W
    JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia.
    Xie L; Ma L; Liu S; Chang L; Wen F
    Int Immunopharmacol; 2021 Jul; 96():107731. PubMed ID: 33965880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies.
    Watanabe N; Mo F; Zheng R; Ma R; Bray VC; van Leeuwen DG; Sritabal-Ramirez J; Hu H; Wang S; Mehta B; Srinivasan M; Scherer LD; Zhang H; Thakkar SG; Hill LC; Heslop HE; Cheng C; Brenner MK; Mamonkin M
    Mol Ther; 2023 Jan; 31(1):24-34. PubMed ID: 36086817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape.
    Dai Z; Mu W; Zhao Y; Cheng J; Lin H; Ouyang K; Jia X; Liu J; Wei Q; Wang M; Liu C; Tan T; Zhou J
    Signal Transduct Target Ther; 2022 Mar; 7(1):85. PubMed ID: 35332132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long Terminal Repeat CRISPR-CAR-Coupled "Universal" T Cells Mediate Potent Anti-leukemic Effects.
    Georgiadis C; Preece R; Nickolay L; Etuk A; Petrova A; Ladon D; Danyi A; Humphryes-Kirilov N; Ajetunmobi A; Kim D; Kim JS; Qasim W
    Mol Ther; 2018 May; 26(5):1215-1227. PubMed ID: 29605708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-depletion of TRBC1+ T cells promotes the therapeutic efficacy of anti-TRBC1 CAR-T for T-cell malignancies.
    Zhang C; Palashati H; Rong Z; Lin N; Shen L; Liu Y; Li S; Yu B; Yang W; Lu Z
    Mol Cancer; 2020 Nov; 19(1):162. PubMed ID: 33218364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection.
    Jiang J; Chen J; Liao C; Duan Y; Wang Y; Shang K; Huang Y; Tang Y; Gao X; Gu Y; Sun J
    Leukemia; 2023 Aug; 37(8):1660-1670. PubMed ID: 37391486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia.
    Gomes-Silva D; Atilla E; Atilla PA; Mo F; Tashiro H; Srinivasan M; Lulla P; Rouce RH; Cabral JMS; Ramos CA; Brenner MK; Mamonkin M
    Mol Ther; 2019 Jan; 27(1):272-280. PubMed ID: 30391141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of ζ-deficient CARs into the CD3ζ gene conveys potent cytotoxicity in T and NK cells.
    Kath J; Franke C; Drosdek V; Du W; Glaser V; Fuster-Garcia C; Stein M; Zittel T; Schulenberg S; Porter CE; Andersch L; Künkele A; Alcaniz J; Hoffmann J; Abken H; Abou-El-Enein M; Pruß A; Suzuki M; Cathomen T; Stripecke R; Volk HD; Reinke P; Schmueck-Henneresse M; Wagner DL
    Blood; 2024 Jun; 143(25):2599-2611. PubMed ID: 38493479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Universal Anti-CD7 CAR-T Cells Targeting T-ALL and Functional Analysis of CD7 Antigen on T/CAR-T Cells.
    Xie L; Gu R; Yang X; Qiu S; Xu Y; Mou J; Wang Y; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Hum Gene Ther; 2023 Dec; 34(23-24):1257-1272. PubMed ID: 37861302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML).
    Lu Y; Liu Y; Wen S; Kuang N; Zhang X; Li J; Wang F
    J Transl Med; 2022 Dec; 20(1):600. PubMed ID: 36517851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy.
    Kim MY; Cooper ML; Jacobs MT; Ritchey JK; Hollaway J; Fehniger TA; DiPersio JF
    JCI Insight; 2021 Aug; 6(16):. PubMed ID: 34423790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of CD3 and CD7 in T-cell malignancies: a quantitative study by flow cytometry.
    Ginaldi L; Matutes E; Farahat N; De Martinis M; Morilla R; Catovsky D
    Br J Haematol; 1996 Jun; 93(4):921-7. PubMed ID: 8703826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial.
    Lu P; Liu Y; Yang J; Zhang X; Yang X; Wang H; Wang L; Wang Q; Jin D; Li J; Huang X
    Blood; 2022 Jul; 140(4):321-334. PubMed ID: 35500125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lineage determination of CD7+ CD5- CD2- and CD7+ CD5+ CD2- lymphoblasts: studies on phenotype, genotype, and gene expression of myeloperoxidase, CD3 epsilon, and CD3 delta.
    Yoneda N; Tatsumi E; Teshigawara K; Nagata S; Nagano T; Kishimoto Y; Kimura T; Yasunaga K; Yamaguchi N
    Am J Hematol; 1994 Apr; 45(4):310-20. PubMed ID: 7513945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
    Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
    Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7-positive malignancies.
    Chen D; You F; Xiang S; Wang Y; Li Y; Meng H; An G; Zhang T; Li Z; Jiang L; Wu H; Sheng B; Zhang B; Yang L
    Am J Cancer Res; 2021; 11(11):5263-5281. PubMed ID: 34873460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.